Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer: Abstracted from: Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumour response rate. J Clin Oncol 2004; 22:3776–83.

Autor: Yip, Desmond, Goldstein, David
Zdroj: In Cancer Treatment Reviews 2005 31(3):236-241
Databáze: ScienceDirect
Externí odkaz: